Loading...
•
Dec 31, 2024
Capricor Q4 2024 Earnings Report
Capricor reported its Q4 2024 financial results, highlighting a net loss and a decrease in revenue compared to the previous year.
Key Takeaways
Capricor Therapeutics posted a net loss for Q4 2024, with decreased revenue and increased operating expenses. The company maintained a strong cash position and continues advancing its pipeline and regulatory efforts.
Q4 2024 revenue was $11.13 million, down from $12.09 million in Q4 2023.
Net loss of $7.12 million, or $0.16 per share.
Operating expenses increased to $18.83 million in Q4 2024.
Cash, cash equivalents, and marketable securities totaled $151.52 million at year-end 2024.
Forward Guidance
Capricor expects its current cash balance to fund operations into 2027 while advancing regulatory approvals and manufacturing expansion.
Positive Outlook
- FDA accepted BLA for deramiocel with Priority Review.
- PDUFA target action date set for August 31, 2025.
- Cash balance sufficient to support operations into 2027.
- Strong clinical data demonstrating deramiocel’s potential.
- EMA granted Orphan Drug and ATMP designations.
Challenges Ahead
- Revenue declined compared to the previous year.
- Increased operating expenses impacting profitability.
- Ongoing net losses quarter-over-quarter.
- Pending regulatory milestones create uncertainty.
- Potential delays or challenges in manufacturing scale-up.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...